Czech National Bank Grows Position in Abbott Laboratories $ABT

Czech National Bank grew its stake in Abbott Laboratories (NYSE:ABT) by 4.7% during the second quarter, Holdings Channel.com reports. The fund owned 495,786 shares of the healthcare product maker’s stock after acquiring an additional 22,212 shares during the period. Czech National Bank’s holdings in Abbott Laboratories were worth $44,988,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ABT. PensionDanmark Pensionsforsikringsaktieselskab raised its position in Abbott Laboratories by 16.2% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 342,554 shares of the healthcare product maker’s stock worth $31,083,000 after buying an additional 47,845 shares during the last quarter. Red Spruce Capital LLC grew its stake in Abbott Laboratories by 24.3% during the 2nd quarter. Red Spruce Capital LLC now owns 36,210 shares of the healthcare product maker’s stock valued at $3,286,000 after purchasing an additional 7,078 shares in the last quarter. St. Louis Financial Planners Asset Management LLC bought a new position in Abbott Laboratories during the second quarter worth $4,903,000. Westmount Partners LLC boosted its position in Abbott Laboratories by 6.6% during the 2nd quarter. Westmount Partners LLC now owns 4,734 shares of the healthcare product maker’s stock valued at $430,000 after purchasing an additional 294 shares during the period. Finally, 55 North Private Wealth LLC acquired a new stake in Abbott Laboratories in the 2nd quarter valued at approximately $209,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on ABT. Citigroup upped their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Weiss Ratings downgraded shares of Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 23rd. Oppenheimer cut their target price on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Robert W. Baird initiated coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 target price for the company. Finally, Leerink Partners cut their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research note on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $118.17.

Abbott Laboratories Trading Up 2.0%

NYSE ABT opened at $107.86 on Friday. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $186.63 billion, a PE ratio of 34.90, a price-to-earnings-growth ratio of 2.05 and a beta of 0.59. The business’s 50-day moving average price is $95.06 and its two-hundred day moving average price is $99.97.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same period last year, the business posted $1.26 EPS. The firm’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s payout ratio is currently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.